Overall, our findings highlight a novel mechanistic role of the MK2-TTP axis in Stx-mediated pathogenesis, offering valuable insights for the development of targeted therapies in Shiga toxin-associated diseases, including hemolytic uremic syndrome. This evidence concerns the gene MAPKAPK2 and hemolytic-uremic syndrome.